Erratum to: Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort (Breast Cancer Research and Treatment (2014) 145, (535-543) DOI: 10.1007/s10549-014-2934-6);Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 535-543

  Fournier, Agnès ^a,b,c   Mesrine, Sylvie ^a,b,c   Dossus, Laure ^a,b,c   Boutron Ruault, Marie Christine ^a,b,c   Clavel Chapelon, Françoise ^a,b,c   Chabbert Buffet, Nathalie ^d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HÔPITAL TENON   (France)

Author keywords

Breast cancer; Cohort study; Estrogens; Menopausal hormone therapy; Progestagens

Indexed keywords

DYDROGESTERONE; GESTAGEN; PROGESTERONE; ESTROGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY ANALYSIS; ADVERSE EFFECTS; BODY MASS; BREAST NEOPLASMS; CHEMICALLY INDUCED; HORMONE SUBSTITUTION; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE;

AGED; BODY MASS INDEX; BREAST NEOPLASMS; COHORT STUDIES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; QUESTIONNAIRES; RISK FACTORS;

EID: 84901664352     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3067-7     Document Type: Erratum

References (26)

1. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens-part A: pharmaceuticals. Lancet Oncol 10:13-14
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
3. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427 (Pubitemid 36999703)
4. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674 (Pubitemid 46631679)
5. Ringa V, Fournier A (2008) Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)? Rev Epidemiol Sante Publique 56:e8-e12
6. Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66:1-7. doi: 10.1136/jech.2008.083774
7. Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11:545-560 (Pubitemid 41631306)
8. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G, WHI Investigators (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573-587
9. Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103-111 (Pubitemid 350179584)
10. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 26:1260-1268
11. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2009) Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27:5138-5143
12. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059 (Pubitemid 27437855)
13. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 81:339-344 (Pubitemid 29165190)
14. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491 (Pubitemid 30062864)
15. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 17:3150-3160. doi: 10.1158/1055-9965.EPI-08-0435
16. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C (2009) Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 115:936-945. doi: 10.1002/cncr.24101
17. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366-2378. doi: 10.1158/1055-9965.EPI-10- 0162
18. Beral V, Reeves G, Bull D, Green J, Million Women Study Collaborators (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103:296-305. doi: 10.1093/jnci/djq527
19. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL (2013) Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105:526-535. doi: 10.1093/jnci/djt043
20. Racine A, Bijon A, Fournier A, Mesrine S, Clavel-Chapelon F, Carbonnel F, Boutron-Ruault MC (2013) Menopausal hormone therapy and risk of cholecystectomy: A prospective study based on the French E3N cohort. CMAJ 185:555-561. doi: 10.1503/cmaj.121490
21. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, Weber AL, Doody DR, Wingo PA, McDonald JA, Malone KE, Folger SG, Spirtas R (2002) Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 100:1148-1158 (Pubitemid 35449180)
22. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593-600 (Pubitemid 34760816)
23. Allen NE, Tsilidis KK, Key TJ et al (2010) Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 172:1394-1403. doi: 10.1093/aje/kwq300
24. Santen RJ (2002) To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 87:3007-3012 (Pubitemid 34816335)
25. Banks E, Beral V, Cameron R, Hogg A, Langley N, Barnes I, Bull D, Elliman J, Harris CL (2001) Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 6:357-363 (Pubitemid 33138827)
26. Sandini L, Pentti K, Tuppurainen M, Kroger H, Honkanen R (2008) Agreement of self-reported estrogen use with prescription data: An analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 15:282-289 (Pubitemid 351354989)